The Manufacturers Life Insurance Company Sells 796 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

The Manufacturers Life Insurance Company lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.7% in the third quarter, HoldingsChannel reports. The fund owned 107,752 shares of the medical equipment provider’s stock after selling 796 shares during the period. The Manufacturers Life Insurance Company’s holdings in Lantheus were worth $11,826,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC boosted its holdings in Lantheus by 184.1% in the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 208 shares during the period. Signaturefd LLC boosted its stake in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares during the period. Nkcfo LLC bought a new stake in shares of Lantheus in the second quarter valued at approximately $47,000. UMB Bank n.a. grew its position in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new position in Lantheus during the 3rd quarter worth $51,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

LNTH stock opened at $89.58 on Tuesday. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The stock has a market cap of $6.23 billion, a price-to-earnings ratio of 14.91 and a beta of 0.51. The company has a 50 day simple moving average of $100.90 and a 200 day simple moving average of $97.43.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on LNTH. Redburn Atlantic initiated coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. JMP Securities reduced their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, Truist Financial reiterated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $125.71.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.